Ali Behbahani Sells 4,445,093 Shares of Genocea Biosciences, Inc. (NASDAQ:GNCA) Stock
Genocea Biosciences, Inc. (NASDAQ:GNCA – Get Rating) Director Ali Behbahani sold 4,445,093 shares of Genocea Biosciences stock in a transaction dated Wednesday, May 25th. The shares were sold at an average price of $0.08, for a total transaction of $355,607.44. The sale was disclosed in a filing with the SEC, which is available through this link.
Shares of GNCA traded down $0.02 during trading hours on Thursday, hitting $0.07. The company had a trading volume of 32,288,509 shares, compared to its average volume of 4,308,155. The firm has a market cap of $4.35 million, a price-to-earnings ratio of -0.12 and a beta of 1.90. The business has a fifty day moving average of $0.60 and a 200-day moving average of $0.96. Genocea Biosciences, Inc. has a 12 month low of $0.06 and a 12 month high of $2.68. The company has a quick ratio of 2.24, a current ratio of 1.35 and a debt-to-equity ratio of 0.24.
Genocea Biosciences (NASDAQ:GNCA – Get Rating) last announced its quarterly earnings data on Thursday, March 10th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.01). During the same period in the previous year, the business posted ($0.18) EPS. On average, equities analysts expect that Genocea Biosciences, Inc. will post -0.5 EPS for the current fiscal year.
A number of equities research analysts recently weighed in on GNCA shares. Stifel Nicolaus downgraded shares of Genocea Biosciences from a “buy” rating to a “hold” rating in a research note on Friday, April 29th. HC Wainwright downgraded shares of Genocea Biosciences from a “buy” rating to a “neutral” rating in a research note on Friday, April 29th. Robert W. Baird dropped their price target on shares of Genocea Biosciences from $8.00 to $3.00 in a research note on Monday, April 11th. Finally, StockNews.com started coverage on shares of Genocea Biosciences in a research note on Saturday, May 21st. They set a “sell” rating for the company.
A number of institutional investors have recently added to or reduced their stakes in GNCA. Geode Capital Management LLC grew its position in Genocea Biosciences by 11.3% in the 4th quarter. Geode Capital Management LLC now owns 206,880 shares of the biotechnology company’s stock valued at $239,000 after purchasing an additional 20,938 shares during the period. Renaissance Technologies LLC acquired a new stake in Genocea Biosciences in the 4th quarter valued at $32,000. Acadian Asset Management LLC acquired a new stake in Genocea Biosciences in the 4th quarter valued at $25,000. Northern Trust Corp boosted its holdings in Genocea Biosciences by 25.4% during the 4th quarter. Northern Trust Corp now owns 70,837 shares of the biotechnology company’s stock worth $82,000 after acquiring an additional 14,368 shares during the last quarter. Finally, Commonwealth Equity Services LLC boosted its holdings in Genocea Biosciences by 49.4% during the 4th quarter. Commonwealth Equity Services LLC now owns 31,981 shares of the biotechnology company’s stock worth $37,000 after acquiring an additional 10,576 shares during the last quarter. Hedge funds and other institutional investors own 59.25% of the company’s stock.
Genocea Biosciences Company Profile (Get Rating)
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient’s CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient’s tumor.
Receive News & Ratings for Genocea Biosciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Genocea Biosciences and related companies with MarketBeat.com’s FREE daily email newsletter.